> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-169/
- Published: 2018-03-04T12:00:00.000Z
- Updated: 2026-09-14T23:27:12.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140902

[**Draft Guide on Product Tracing Standardized Data**](https://www.fdaweb.com/draft-guide-on-product-tracing-standardized-data/)  
*Federal Register* notice: FDA makes available a draft guidance on “Standardization of Data and Documentation Practices for Product Tracing.” 03/02/2018

[**Guide on Genomic Sampling and Managing Data**](https://www.fdaweb.com/guide-on-genomic-sampling-and-managing-data/)  
*Federal Register* notice: FDA makes available a guidance entitled “E18 Genomic Sampling and Management of Genomic Data.” 03/02/2018

[**FDA/Canada Joint ICH Regional Meeting**](https://www.fdaweb.com/fda-canada-joint-ich-regional-meeting/)  
*Federal Register* notice: FDA announces a regional public meeting entitled “U.S. Food and Drug Administration and Health Canada Joint Regional Consultation on the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).” 03/02/2018

[**Comments Sought on Susceptibility Test Interpretive Criteria**](https://www.fdaweb.com/comments-sought-on-susceptibility-test-interpretive-criteria/)  
*Federal Register* notice: FDA reopens a docket for public comment on the susceptibility test interpretive criteria for antibacterial and antifungal drugs provided by FDA on its Susceptibility Test Interpretive Criteria Web page established 12/13/2017\. 03/01/2018

[**Panel Meeting to Review Glucose Monitor**](https://www.fdaweb.com/panel-meeting-to-review-glucose-monitor/)  
*Federal Register* notice: FDA announces a 3/29-30 Clinical Chemistry and Clinical Toxicology Devices Panel meeting. 02/28/2018

[**Information Collection Extension on Orphan Product Meetings**](https://www.fdaweb.com/information-collection-extension-on-orphan-product-meetings/)  
*Federal Register* notice: FDA submits for OMB approval an information collection extension for “Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff on Meetings With the Office of Orphan Products Development.” 02/28/2018

[**Class 2 for Lynch Syndrome Test Systems**](https://www.fdaweb.com/class-2-for-lynch-syndrome-test-systems/)  
*Federal Register* notice: FDA classifies Lynch syndrome test systems into Class 2 (special controls). 02/27/2018

[**Correction: FDA Says Baxter Clinolipid NDA Not Withdrawn**](https://www.fdaweb.com/correction-fda-says-baxter-clinolipid-nda-not-withdrawn/)  
Federal Register notice: FDA corrects a 6/21/2017 Federal Register notice that incorrectly announced the withdrawal of a Baxter Healthcare NDA for Clinolipid 20%. 02/27/2018